Contineum Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc. (ticker: CTNM) is a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States, and it is best viewed as a clinical-stage biotech rather than a commercial-stage drug maker. The company is headquartered in San Diego, California, and was incorporated in Delaware in 2009. In November 2023, it changed its name from Pipeline Therapeutics, Inc. to Contineum Therapeutics, Inc. to reflect a broader focus on neuroscience, inflammation, and immunology, or NI&I. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030614/ctnm-20260331.htm?utm_source=openai)) Contineum’s core business is the discovery and development of novel oral small-molecule therapeutics aimed at diseases with significant unmet medical need. The company’s model is centered on internal R&D and clinical advancement, not on generating revenue from marketed products. Its lead asset is PIPE-791, a brain-penetrant LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis (IPF). Another key program is PIPE-307, a selective muscarinic M1 receptor antagonist being advanced in neurological indications. Contineum has also nominated CTX-343, a peripherally restricted LPA1R antagonist, underscoring that the company is building a multi-asset discovery platform around related biology. ([contineum-tx.com](https://contineum-tx.com/pipeline/?utm_source=openai)) From a competitive standpoint, Contineum occupies a specialized niche within the biotech universe. Its investment case is built on scientific differentiation, target validation, and the ability to move programs through the clinic with convincing safety and efficacy data. The portfolio spans two attractive therapeutic themes: fibrosis/respiratory disease through PIPE-791 and central nervous system disease through PIPE-307. A notable strategic feature is the global license and development agreement with Janssen for PIPE-307, which provides external validation and potentially broadens the path to development and future value creation. ([ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/pipeline-therapeutics-announces-global-license-and-development/?utm_source=openai)) Recent company highlights have centered on clinical execution and milestone delivery. Throughout 2025, Contineum reported financial and operational updates showing higher R&D spending, largely driven by advancement of PIPE-791 and PIPE-307, while also pointing to upcoming topline clinical readouts. For equity investors, CTNM should therefore be seen as a high-risk, high-upside clinical biotech with a clearly defined pipeline, meaningful scientific ambition, and significant dependence on trial outcomes and partnership execution. ([ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/contineum-therapeutics-reports-second-quarter-2025-financial/?utm_source=openai))